Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke
Status:
Not yet recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
Two recent randomized controlled trials (BAOCHE and ATTENTION) have confirmed the efficacy
and safety of endovascular therapy in patient with acute ischemic stroke (AIS) due to basilar
artery occlusion (BAO). However, it is still inconclusive whether there is any differences
between endovascular therapy with or without bridging intravenous thrombolysis in acute BAO.
So far, no randomized controlled trial has been conducted specifically for endovascular
therapy with or without intravenous thrombolysis for ischemic stroke due to BAO. Therefore,
this study plans to conduct a prospective, multicenter, randomized controlled trial to
compare the functional outcomes between endovascular therapy with and without intravenous
thrombolysis in patient with AIS due to BAO.
This study is a multicenter, parallel, open label, randomized controlled trial comparing
direct endovascular therapy versus endovascular therapy bridging intravenous thrombolysis
(IVT). This study intends to include patients with AIS due to BAO fulfilling the following
inclusion criteria: patients with AIS caused by BAO confirmed by CTA/MRA/DSA; IVT can be
started within 4.5 hours after symptoms onset; Age ≥ 18 years old; NIHSS score ≥ 6.
The main outcome is the 3-month mRS scale score. Secondary outcomes included NIHSS at 24
hours and 7 days after surgery, CTA vascular recanalization at 24-72 hours, mRS at 5-7 days,
and infarct volume. The safety outcomes included 90-day mortality and the incidence of sICH.